The issue of appropriate testing strategies has been raised for the genotoxicity assessment of nanomaterials. Recently, efforts have been made to evaluate the adequacy of Organisation for Economic Co-operation and Developmentstandardised tests to assess the genotoxicity of nanomaterials. The aim of this review was to examine whether the current guideline for the in vitro micronucleus (MN) assay is applicable for testing nanomaterials. From a Pubmed literature search, 21 available studies were identified for analysis. We reviewed all protocols used for testing nanomaterials with the in vitro MN assay. All studies were categorised based on the particle type and size. Different aspects of the protocols were evaluated such as the exposure (duration and doses), the cytochalasin-B treatment, serum levels and cytotoxicity assessment. Sixteen of the 21 studies demonstrated increased frequencies of MN. Some recommendations regarding the protocol were formulated to maximise sensitivity and avoid false negatives. Determination of the cellular dose was advised for a better interpretation of MN frequency results. The level of serum can modulate the cellular response, therefore the serum percentage used should enable cell growth and proliferation and a maximal sensitivity of the assay. Furthermore, different types of cytochalasin-B treatment were used, co-treatment, posttreatment and delayed co-treatment. In order to avoid decreased cellular uptake as a consequence of actin inhibition, post-treatment or delayed co-treatment is suggested. Exposure during mitosis should be recommended to allow contact with the chromatin or mitotic apparatus for nanomaterials that are unable to cross the nuclear membrane. With these adaptations, the in vitro MN assay can be recommended for genotoxicity testing of nanomaterials.
Introduction
The development and production of nanomaterials, defined as materials with at least one dimension smaller than 100 nm, is growing steadily. With the increasing concern about the safety of nanomaterials, the issue of adequate testing strategies has been raised. As the physico-chemical characteristics of nanomaterials are ruled not only by classic physics but also by quantum physics, the appropriateness of genotoxicity assays developed for the testing of chemicals and therefore the validity of published data can be questioned. Three reviews addressed these issues previously (1) (2) (3) . Opinions differ on how to proceed and which approaches should be favoured. Gonzalez et al. (1) and Singh et al. (3) advise to investigate the modes of action of nanomaterials in addition to the use of standardised tests enabling the validation of the existing tests for nanomaterials or development of new tests. Landsiedel et al. (2) recommend the intelligent use of standardised tests for assessment of potential genotoxic effects of nanomaterials, thereby facilitating the comparison of the obtained results.
In 2006, the Organisation for Economic Co-operation and Development (OECD) established the Working Party on Manufactured nanomaterials (WPMNs). One of its objectives is reviewing the current test guidelines for their applicability to manufactured nanomaterials. In their preliminary review of OECD test guidelines (4), the WPMN advices to perform the following in vitro genotoxicity tests for nanomaterials: bacterial reverse mutation test (OECD TG 471), in vitro mammalian chromosome aberration test (OECD TG 473) and in vitro mammalian cell gene mutation test (OECD TG 476). The WPMN advises the use of both bacterial and mammalian cell systems, given the reservations expressed previously about the use of bacterial systems for nanomaterial testing (1) (2) (3) . Drawing conclusions without extensive examination of the tests for their applicability to nanomaterial testing can lead to premature conclusions and erroneous classification.
The aim of this current review is to discuss specifically whether the in vitro micronucleus (MNinv) test as described in the draft OECD guideline (OECD TG 487) is appropriate for the genotoxicity testing of nanomaterials. If not, what adaptations should be made or what further research should be recommended for the development of an appropriate MN test?
The first recommendations describing a harmonised protocol for the in vitro micronucleus (MN) assay were published by Kirsch-Volders et al. (5, 6) . The final OECD guideline (OECD TG 487) has been approved by the Working Group of National Coordinators of the Test Guidelines Programme and final adoption is expected in 2010 (for review, see ref 7) .
In this review, we consider all available published studies applying the in vitro MN assay for the genotoxicity testing of nanomaterials and compare the different protocols used. Furthermore, we highlight the difficulties, shortcomings and the issues deserving further research.
Review of studies applying the in vitro MN assay for nanomaterial testing
Twenty-one studies were selected based on a Pubmed literature search with keywords: 'micronucleus assay AND nanomaterials' and 'micronucleus assay AND nanoparticles'. Only studies fully available were selected; abstracts of publications and from scientific meetings were not included. No studies were found that applied flow cytometry or automated image analysis for the quantification of MN frequencies after in vitro treatment with nanomaterials. Concentration not given, 12-h delayed co-treatment
Iron oxide Dextran USPION MCL-5 (human) 24 h; 1, 10, 100 lg/ml 3 lg/ml co-treatment 1 Data not shown À (13) Dextran USPION MCL-5 24 h; 10, 100, 250 lg/ml 3 lg/ml post-treatment 1 Data not shown þ (10 lg/ml) (13) 
Information on the particle type and size, the cell type used, the exposure protocol, the cytochalasin-B treatment, the serum percentage, the method with which the top dose was determined and the results are given. Results are represented as þ when statistically significant effects were observed, as (þ) when no statistically significance was determined but a positive trend was visible and asÀ when no statistical genotoxic effect was detected. Concentrations between brackets in the results column correspond to the lowest statistically significant concentration. A549, human lung carcinoma cell line; BALB/3T3, mouse fibroblasts; BEAS-2B, human bronchial epithelial cells; % BN, percentage binucleated cells; CBPI, cytokinesis-block proliferation index; CFE, colony forming efficiency; CHO, Chinese hamster ovarian cells; CHO-K1, Chinese hamster ovarian cell line; HEK293, human embryonic kidney cell line; Hela, human cervical cancer cell line; IMR-90, human normal fibroblasts; L-02, human fetus hepatic cell line; LDH, lactate dehydrogenase; MCF-7, human breast cancer cell line; MCL-5, human lymphoblastoid B-cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; ATP, adenosine triphosphate; MWCNT, multi-walled carbon nanotube; NIH-3T3, a mouse embryonic fibroblast cell line; NDI, nuclear division index; RAW 264.7, a murine macrophage cell line; RLE, rat lung epithelial cells; RTG-2, cells from gonadal tissue of the rainbow trout; SHE, Syrian hamster embryo; U251, a human glioblastoma cell line; WIL2-NS, a human lymphoblastoid cell line. Table I 
In vitro MN assay for assessment of nanomaterials
with the in vitro MN test. Studies were categorised based on nanomaterial type (chemical composition) and size. The in vitro MN assay protocols are described in
Results and discussion
Overview of the individual studies Aluminium oxide. Only one study was retrieved where 28 nm Al 2 O 3 particles were tested in vitro in CHO-K1 cells. These particles induced a statistically significant increase in MN frequencies at a concentration of 0.5 lg/ml (8).
Carbon nanomaterials. In six studies, the in vitro MN assay was applied to test the genotoxic potential of carbon nanomaterials, including carbon black, hydroxyl fullerenes, graphite nanofibres, single-walled carbon nanotube (SWCNT) and multi-walled carbon nanotube (MWCNT). Carbon black and graphite nanofibres did not induce elevated MN frequencies (11, 14) . In contrast, long-term and short-term exposure to C 60 (OH) 24 did induce higher frequencies of MN (9,10).
MWCNT of different dimensions and preparations elicited significant induction of MN frequencies and this was in different cell line/types (RAW 264.7, whole blood, RLE and MCF-7) (11, 12, 16 Cobalt. Cobalt nanoparticles were tested in three studies, two of which tested nanoparticles consisting solely of cobalt (17, 18) and one study tested nanoparticles consisting of CoCr (19) . All cobalt-containing nanoparticles tested increased the MN frequencies significantly.
Iron oxide. Doak et al. (13) investigated iron oxide particles, more specifically dextran-coated ultrafine superparamagnetic iron oxide nanoparticles (Dextran USPION) in the human MCL-5 cell line. Three different protocols for the in vitro MN assay were used, but only the protocol where the cytochalasin-B was added after nanomaterial treatment resulted in increased MN frequencies.
Silicon. The genotoxic effects of SiO 2 nanoparticles were investigated in two studies. Wang et al. (21) demonstrated that crystalline 7.21 nm SiO 2 nanoparticles induce MN. In contrast, no statistically significant induction of MN was found by amorphous SiO 2 nanoparticles of 16, 60 and 104 nm. In this study, MN frequencies were expressed in function of mass dose, number of particles and surface area and this when taking into account both the nominal and cellular dose. They showed that there was a statistically significant positive correlation between the fold increase of MN and the particle number or surface area, considering both nominal and cellular dose. No significant correlation was found between the fold increase of MN and mass dose. Silver Only one study on the in vitro genotoxicity of Ag nanoparticles is included in this review. In that study, 6-20nm Ag nanoparticles were tested on two different cell lines (U251, a human glioblastoma cell line and IMR-90, normal human fibroblasts). Ag nanoparticles induced MN in both cell lines with similar levels for the two cell lines (22) .
Titanium dioxide. The genotoxic potential of titanium dioxide was examined in eight different studies. Four of them did not specify the crystalline structure (anatase or rutile) of these particles. These studies investigated TiO 2 particles with a maximum diameter of 20 nm in different cell lines, of both human and rodent origin, and revealed statistically significant increase of MN frequencies (8, (23) (24) (25) .
Treatment of BEAS-2B cells with 100% anatase particles (10 and 200 nm) induced a statistically significant increase of MN frequencies. However, treatment with 100% anatase particles with a diameter .200 nm and 100% rutile 200 nm nanoparticles did not (26) .
Results obtained after treatment with mixtures of anatase and rutile TiO 2 nanoparticles as treatment with particles in the same size range and same mixture ratios (anatase being the majority %) lead to different outcomes for different cell types and treatment times, with a 48 h exposure reaching significance (28, 29) . In contrast, a 48-h study with a different mixture of anatase and rutile TiO 2 nanoparticles (with rutile being the majority %) was not significant (27) .
Observations related to the published protocols

Exposure protocol
The majority of studies exposed cells to nanomaterials for at least 24 h. Only five studies performed shorter exposures (3, 6 or 12 h). A 12-h exposure of SHE (Syrian hamster embryo) fibroblasts to TiO 2 nanoparticles (,20 nm) did not induce a significant increase of MN. Longer exposure times are more informative as they allow uptake of nanomaterials, which has been shown to be time-dependent (31) . Furthermore, an exposure during mitosis is generally recommended, at least for those nanomaterials that cannot cross the nuclear membrane and might need to be in contact with the chromatin to exert their effect.
Cytochalasin-B treatment
Four types of cytochalasin-B treatment are used in the different studies: co-treatment, post-treatment, delayed co-treatment and no treatment (Figure 1) . Doak et al. (13) demonstrated that for Dextran-UPSION exposure to MCL-5 cells (in 1% serum), a post-treatment with cytochalasin-B induced a significant and dose-dependent increase of MN frequencies, which was not observed when a co-treatment was performed or when the in vitro MN assay was performed without cytochalasin-B. The authors suggested that it is likely due to a lower statistical sensitivity of the test, in that in the absence of cytochalasin-B, double the number of cells needs to be scored to observe the same level of MN. The alternative reason for a false-negative result when cytochalasin-B is not used is an underestimate of MN expression because of inhibition of nuclear division (i.e. cytostatic effect); non-dividing cells cannot express MN but they cannot be excluded or identified if cytochalasin-B is not used to distinguish them from dividing cells identified as binucleates. The inclusion of non-divided mononuclear cells in the denominator of the MN frequency ratio which may increase with genotoxin dose may result in false-negative results being generated. A comparison of different types of cytochalasin-B treatment was also performed on BEAS-2B cells exposed to SWCNT and again a clearer response was observed after posttreatment with cytochalasin-B (13).
Serum percentages
Most of the studies performed the in vitro MN assay with 10% serum. Only one study performed it in the absence of serum (14) . In that study, there was no significant induction of MN in BEAS-2B cells after treatment with CNT and graphite nanofibres under serum-free conditions. In contrast, Doak et al. (13) found significant frequencies of MN when serum levels were only 2%, but not if 10% serum was used after treatment with SWCNT in the same cell line.
Research gaps and future directions
The major difficulties encountered when performing the in vitro MN assay with nanomaterials are common to all in vitro tests assessing their genotoxicity.
(I) Dosimetry: how to estimate the dose applied. Two complementary papers give their recommendations on this issue considering the cytotoxicity of nanomaterials and discuss the need for measurements of the cellular dose (32, 33) . For cytotoxicity assays, it has been shown that because of the forces present in the culture medium (gravitation, diffusion and convection), the majority of the nanoparticles would collide with adherent cells and exert biological effects (31) . As far as genotoxicity is concerned and in particular for the in vitro MN assay, only one paper addressed this question, to the best of our knowledge, and found that for A549 lung carcinoma cells treated with amorphous silica nanoparticles, both nominal and cellular dose can be used (20) . However, additional information is expected from the assessment of the cellular dose when intracellular targets are assessed. In addition, when considering the in vitro cytochalasin-B MN assay, possible differences between nominal and cellular dose might result from differential uptake under cytochalasin-B treatment. Therefore, these measurements should be recommended when possible. Studies should also be designed so that the nanoparticle concentration is measured directly in the same cells in which MN Recent considerations about the in vitro MN assay should also be applied to the testing of nanomaterials, in particular when subtoxic concentrations (not the 55 AE 5% toxicity as top dose) are tested to reflect better the real exposure situation and if an aneugenic mode of action is suspected. This means practically to enhance as much as possible the sensitivity of the assay and to maximise its capacity to detect aneugens. Although the OECD draft guideline for the in vitro MN assay (MNvit guideline 478) does not recommend different numbers of cells to be scored in the presence or absence of cyotochalasin-B, expertise from different laboratories (7, 35) and statistical evidence indicate that scoring more cells when the in vitro test is performed without cytochalasin-B should be considered. Moreover, as already demonstrated by Elhajouji et al. (36) for mitotic slippage, recommended by us (37) and confirmed by an interlaboratory exercise on cell lines (34, 35) , scoring of MN in mononucleates in cytokinesis-blocked cultures is a sensitive tool to detect aneugens. If in the future, aneugenicity is confirmed to be a major mode of action of nanomaterials, the use of cytochalasin-B (delayed co-treatment) should be recommended for cell lines as well. Final recommendation should await additional data obtained with a larger range of particles and protocol variants.
(V) Necessity of a mitosis in the presence of nanoparticles:
several papers mention that nanoparticles do not cross the nuclear membrane and therefore may not come into contact with the chromatin. Hence, it is critical that cells should undergo mitosis during the treatment period allowing contact with chromatin as soon as disintegration of the nuclear membrane commences. Adequate exposure protocols, taking into account the average cell cycle of the cell lines used, should address this issue.
In conclusion, several types of nanomaterials were shown to induce a significant increase of MN frequencies. The in vitro MN test is quite appropriate to screen nanoparticles for potential genotoxicity. However, based on previous considerations and to avoid false negatives, final acceptance of an appropriate design of the in vitro MN test for the hazard assessment of nanomaterials will require additional data, in particular on (i) treatment schedule before adding cytochalasin-B, including exposure during one mitosis and (ii) comparison of effects with 10% serum, reduced serum levels or in absence of serum.
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